Financings Of The Fortnight: Is Buoyant Biotech IPO Scene Altering Private Biotech M&A Trends?
This article was originally published in The Pink Sheet Daily
When the IPO spigot runs dry, there’s M&A aplenty, and when the IPO wine is flowing, M&A slows down, right? FOTF tackles some conventional wisdom; plus deals from Acadia, Neurocrine, Aquinox, and Human Longevity.
You may also be interested in...
The former Celera CEO has raised $70 million for a new organization that will use genomic, biochemical and microbiome data to find stem cell-based treatments for aging-related disorders.
With no public market to provide competition, the theory among biotech's optimists was that Big Pharma would step in and buy lots of bargains. But cheap prices and easy availability haven't increased drug company appetites: They will only buy what they really want. Deal volumes, both for M&A and alliances, are falling, while Big Pharma has learned to put more of the risk back on biotech. What will change this dynamic, putting more bargaining into biotech hands, is the revival of the public market - and there are hints that such a revival may be on the way.
Experts share what they believe are the solutions to key manufacturing challenges, such as lowering cost of goods and centralized manufacturing, in the cell and gene therapy sector.